Groowe Groowe BETA

US Stock Market News

Stay on top of the US stock market with real-time breaking news and market-moving stories. Our platform continuously aggregates updates from trusted financial news sources, giving traders and investors a fast overview of events that may impact stock prices.

Whether you're tracking specific companies or scanning the broader market, the news feed helps you quickly identify important developments as they happen.

Create an account to access the live news feed. Access is free while the platform is in beta. Visitors without an account can still browse the latest headlines with a 15-minute delay.

⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Levi & Korsinsky Urges York Space Systems Inc (YSS) Shareholders to Act Before Lead Plaintiff Deadline October 30, 2026

accessnewswire.com
YSS

Join Class Action to Recover Losses from Honeywell Aerospace Inc. (HONA) – Contact Levi & Korsinsky Before November 23, 2026

accessnewswire.com
HONA HON

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Astrana Health, Inc. - ASTH

accessnewswire.com
ASTH

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of America's Car-Mart, Inc. - CRMT

accessnewswire.com
CRMT

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FreightCar America, Inc. - RAIL

accessnewswire.com
RAIL

Beneficient Investor News: If You Have Suffered Losses in Beneficient, You Are Encouraged to Contact The Rosen Law Firm About Your Rights

globenewswire.com
BENF

Crypto News: Remittix Announces 300 Million RTX Burn at Launch as JPMorgan Brings Two Tokenized Funds to Solana, Building the Case for a $300 SOL Price Prediction

globenewswire.com
JPM

AST SpaceMobile, Inc. (ASTS) Lawsuit – Investors Urged to Contact Levi & Korsinsky Before November 13, 2026

accessnewswire.com
ASTS

Class Action Lawsuit Filed: Qfin Holdings, Inc. (QFIN) – Join by November 27, 2026 – Contact Levi & Korsinsky

accessnewswire.com
QFIN

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer

prnewswire.com
JNJ
View all news →